Gilead to Acquire Arcellx in $7.8B Deal

Gilead Sciences has entered a definitive agreement to acquire Arcellx in a transaction valued at approximately $7.8 billion. The companies previously partnered through Kite to co-develop and co-commercialize anito-cel for relapsed or refractory multiple myeloma.

Deal terms include $115 per share in cash plus a $5 per share contingent value right tied to cumulative global anito-cel net sales of at least $6B through 2029. The FDA has accepted the BLA for fourth-line anito-cel, with a Dec. 23, 2026 action date. Closing is expected in Q2 2026 via tender offer and second-step merger, with EPS accretion projected to begin in 2028 after approval.